SCHEMBL2926318

SCHEMBL2926318

O=C(Nc1cnc2cc(CN3CCCC3)ccc2c1)c1ccc(-c2ccc(F)cc2)nc1

nearest known ligand 0.82

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 18/20 0.82
HTR2C P28335 13/20 0.82
DYRK1A Q13627 1/20 0.51
TRPV1 Q8NER1 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2926451 0.91 MCHR1 (0.82) MCHR1HTR2C
SCHEMBL5649866 0.90 MCHR1 (1.00) MCHR1HTR2C
SCHEMBL2927588 0.90 MCHR1 (0.80) MCHR1HTR2C
SCHEMBL2923106 0.85 MCHR1 (0.65) MCHR1HTR2CDYRK1ATRPV1
SCHEMBL2926361 0.85 MCHR1 (0.81) MCHR1HTR2C
SCHEMBL2920900 0.84 MCHR1 (0.80) MCHR1HTR2C
SCHEMBL2926180 0.81 MCHR1 (0.82) MCHR1HTR2C
SCHEMBL2927690 0.81 MCHR1 (0.82) MCHR1HTR2C
SCHEMBL2926448 0.81 MCHR1 (0.81) MCHR1HTR2CTRPV1
SCHEMBL5651597 0.81 MCHR1 (1.00) MCHR1HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1285651-B1 MELANIN CONCENTRATING HORMONE ANTAGONISTS TAKEDA PHARMACEUTICAL (JP) 2010-09-01 EP disclosed
US-6930185-B2 Melanin-concentrating hormone antagonist TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-16 US disclosed
US-20040077628-A1 Melanin-concentrating hormone antagonist TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-22 US disclosed
EP-1285651-A1 MELANIN CONCENTRATING HORMONE ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2003-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077628-A1 Melanin-concentrating hormone antagonist MCHR1, MC1R, MCHR2 MCHR1 1/4885HTR2C 107/4885DYRK1A 2468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.